OBJECTIVE: This study examined the association between cardiac function and pulmonary function in hypertensive patients. METHODS: Hypertensive patients without overt cardiovascular disease were enrolled (n = 43; mean ± SD age 71 ± 9 years). Pulmonary function was measured by the percentage of predicted forced vital capacity (%FVC) and the ratio of 1 s forced expiratory volume (FEV1) to FVC (FEV1/FVC ratio). Left ventricular ejection fraction (LVEF) and the ratio of peak early diastolic transmitral flow (E) to peak early diastolic mitral annular velocity (e′) (E/e′ ratio) were assessed using echocardiography. RESULTS: Multiple linear regression analysis revealed that E/e′ was independently associated with %FVC and that LVEF was independently associated with FEV1/FVC ratio. Both LVEF and FEV1/FVC ratio were significantly lower in hypertensive former or current smokers than in hypertensive never smokers. CONCLUSIONS: Subclinical cardiac dysfunction was independently associated with reduced pulmonary function in hypertensive patients. Hypertensive patients with decreased pulmonary function may need preventive care to prevent the progression of heart failure.
HuntSAAbrahamWTChinMH: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation2009; 119: e391–e479.
2.
LamCSLyassAKrainerE Kraigher: Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation2011; 124: 24–30.
3.
SmithGLShlipakMGHavranekEP: Serum urea nitrogen, creatinine, and estimators of renal function: mortality in older patients with cardiovascular disease. Arch Intern Med2006; 166: 1134–1142.
4.
HorwichTBKalantar-ZadehKMacLellanRW: Albumin levels predict survival in patients with systolic heart failure. Am Heart J2008; 155: 883–889.
5.
HawkinsNMPetrieMCJhundPS: Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail2009; 11: 130–139.
6.
BarrRGBluemkeDAAhmedFS: Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med2010; 362: 217–227.
7.
GroenveldHFJanuzziJLDammanK: Anemia and mortality in heart failure patients: A systematic review and meta-analysis. J Am Coll Cardiol2008; 52: 818–827.
8.
ErnstEHammerschmidtDEBaggeU: Leukocytes and the risk of ischemic diseases. JAMA1987; 257: 2318–2324.
9.
HawkinsNMJhundPSSimpsonCR: Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail2010; 12: 17–24.
10.
PunturieriACroxtonTLWeinmannGG: Chronic obstructive pulmonary disease: A view from the NHLBI. Am J Respir Crit Care Med2008; 178: 441–443.
11.
BozkanatETozkoparanEBaysanO: The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease. J Int Med Res2005; 33: 537–544.
McAllisterDAMacLayJDMillsNL: Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med2007; 176: 1208–1214.
14.
MacLayJDMcAllisterDAMillsNL: Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med2009; 180: 513–520.
15.
WallersonDCDevereuxRB: Reproducibility of echocardiographic left ventricular measurements. Hypertension1987; 9: II6–II18.
16.
TeichholzLEKreulenTHermanMV: Problems in echocardiographic volume determinations: echocardiographic—angiographic correlations in the presence of absence of asynergy. Am J Cardiol1976; 37: 7–11.
17.
NishimuraRATajikAJ: Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol1997; 30: 8–18.
18.
SohnDWChaiIHLeeDJ: Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol1997; 30: 474–480.
19.
OmmenSRNishimuraRAAppletonCP: Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation2000; 102: 1788–1794.
20.
NaguehSFMiddletonKJKopelenHA: Doppler tissue imaging: A noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol1997; 30: 1527–1533.
21.
Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med1995; 152: 1107–1136.
22.
LevyDGarrisonRJSavageDD: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med1990; 322: 1561–1566.
23.
VerdecchiaPSchillaciGBorgioniC: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation1998; 97: 48–54.
24.
LangRMBierigMDevereuxRB: Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr2005; 18: 1440–1463.
25.
SinDDManSF: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation2003; 107: 1514–1519.
26.
RidkerPMHennekensCHBuringJE: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med2000; 342: 836–843.
27.
ManSFConnettJEAnthonisenNR: C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax2006; 61: 849–853.
28.
TorzewskiJTorzewskiMBowyerDE: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol1998; 18: 1386–1392.
29.
RidkerPMBuringJECookNR: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation2003; 107: 391–397.
30.
KardysIKnetschAMBleuminkGS: C-reactive protein and risk of heart failure. The Rotterdam Study. Am Heart J2006; 152: 514–520.
31.
ShanthaGPKumarAABhaskarE: Hypertensive retinal changes, a screening tool to predict microalbuminuria in hypertensive patients: A cross-sectional study. Nephrol Dial Transplant2010; 25: 1839–1845.
32.
KangESKimHJKimYM: Serum high sensitivity C-reactive protein is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Res Clin Pract2004; 66 (suppl 1): S115–S120.
33.
HoenigMRBianchiCRosenzweigA: The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure. Curr Vasc Pharmacol2008; 6: 292–300.
34.
BrooksBAFranjicBBanCR: Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab2008; 10: 739–746.
35.
MasugataHSendaSInukaiM: Association between high-sensitivity C-reactive protein and left ventricular diastolic function assessed by echocardiography in patients with cardiovascular risk factors. Tohoku J Exp Med2011; 223: 263–268.
36.
AnzuetoA: Chronic obstructive pulmonary disease. J Int Med Res2001; 29: 49–50.
37.
MacNeeW: Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc2005; 2: 258–266.
